Join
Live feed
·
PRReleasevia Quantisnow
Cabaletta Bio Inc. logo

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

ByQuantisnow·Wall Street's wire, on your screen.
CABA· Cabaletta Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CABA (Cabaletta Bio Inc.) and more on Quantisnow.